Proteovista

Started in 2011, Proteovista develops innovative enabling technologies and research tools to address a key area of drug discovery in cancer and heart disease. Chris co-founded Proteovista and has been a Principal Investigator on five of the company grants from the National Institutes of Health. Our goal at Proteovista LLC is to develop next generation microarray technology and applications for basic research and drug discovery. We also offer custom microarray services, bioinformatics solutions, assay development, and DNA sequence specificity determination using our SNAP technology, fluorescence polarization, and TR-FRET. Mary is the Co-Founder and Chief Scientific Officer of Proteovista and has been a Principal Investigator on 9 grants in both industrial and academic settings. We offer custom microarray services, bioinformatics solutions, assay development, and DNA sequence specificity determination using our SNAP technology. The National Cancer Institute has awarded Proteovista's SBIR grant, Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array.